Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features

Journal of Gastrointestinal Cancer

Volumn 45, Issue 1, 2014, Pages 54-60

  Nasrabadi, Nafiseh Nasri ^a   Ataee, Ramin ^a,b   Abediankenari, Saeid ^c   Shokrzadeh, Mohammad ^a   Najafi, Mojtaba ^d   Hoseini, Seyed Vahid ^e   Jan, Hamed Haghi Amin ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d University of Agricultural Sciences and Natural Resources   (Iran)

^e MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Gastric adenocarcinoma; Gene expression; Melatonin; MT2 receptor

Indexed keywords

COMPLEMENTARY DNA; MELATONIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STOMACH ADENOCARCINOMA; TUMOR LOCALIZATION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, MELATONIN, MT2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896273829     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-013-9552-0     Document Type: Article

References (48)

1. Parkin D et al. Global cancer statistics. CA Cancer J. 2002;55:74-108.
2. ParkinDM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. European Journal of Cancer. 37. Supplement. 2001;8:4-66.
3. Axon A. Symptoms and diagnosis of gastric cancer at early curable stage. Best Pract Res Clin Gastroenterol. 2006;20(4):697-708. (Pubitemid 44391330)
4. Pinto E, Roviello F, Stefano A. Early gastric cancer: report on 142 patients observed over 13 years. Jpn J Clin Oncol. 1994;24:12-9.
5. Sung N et al. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer. 2007;97(5):700-4. (Pubitemid 47339876)
6. WHO, Initiative for Vaccine Research team of the Department of Immunization, Vaccines and Biologicals. Epidemiology of Helicobacter pylori and gastric cancer. In Proceedings of the Fourth Global Vaccine Research Forum. 2004
7. Underwood H, Goldman B. Vertebrate circadian and photoperiodic systems: role of the pineal gland and melatonin. J Biol Rhythms. 1987;5:279-315.
8. Pardridge V. Transport of protein-bound hormones into tissues in vivo. Endocr. 1981;2(1):103-23.
9. Yu H, Reiter R. Melatonin: biosynthesis, physiological effects, and clinical applications. Boca Raton: CRC; 1993.
10. Pandi-Perumal SR et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85(3):335-53.
11. Stefulj J et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243-7. (Pubitemid 32336907)
12. Fiske Vet al. Effect of melatonin alone or in combinationwith human chorionic gonadotropin or ovine luteinizing hormone on the in vitro secretion of estrogens or progesterone by granulosa cells of rats. Endocrinology. 1984;114:407-10.
13. Brzezinski A. Melatonin in humans. N Engl J. 1997;336(3):186-95. (Pubitemid 27034965)
14. Cos S et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008;8(8):691-702.
15. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60(3):97-108.
16. Reiter RJ et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci. 2007;52:11-28.
17. Boutin JA et al. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005;26(8):412-9. (Pubitemid 41039217)
18. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27(2):119-30. (Pubitemid 41558444)
19. Reiter RJ, Manchester L, Tan DX. Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol. 2010;8(3):194-210.
20. Arnao and Hernandez-Ruiz, 2006. The physiological function of melatonin in plants. Landes Bioscience. p. 2012-13
21. Poeggeler B et al. Melatonin-a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann NYAcad Sci. 1994;738:419-20.
22. Reppert, S., D.Weaver, and E. T, 1994. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. 13:1177-85.
23. Reppert S et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92:8734-8.
24. Coughlin CC et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity. 2007;15(3):640-5. (Pubitemid 46643317)
25. Rivara S et al. Melatonin receptor agonists: SAR and application to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;11(8):954-68.
26. Sugden D et al. Melatonin, melatonin receptors and melanophores. Pigment Cell Res. 2004;17(5):454-60.
27. Dubocovich ML et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010;62(3):343-80.
28. Roca AL et al. Structure, characterization and expression of the gene encoding the mouse Mel1a melatonin receptor. Endocrinology. 1996;137:3469-77. (Pubitemid 26250201)
29. Slominski A et al. On the role of melatonin in skin physiology and pathology. Endocrine. 2005;27:137-48.
30. Konturek SJ, Konturek PC, Brzozowski T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J Physiol Pharmacol. 2006;57:51-66. (Pubitemid 46569784)
31. Dubocovich ML, Markowska. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101-10. (Pubitemid 41558442)
32. Lanoix D et al. Expression of melatoninergic receptors in human placental choriocarcinoma cell lines. Hum Reprod. 2006;21:1981-9. (Pubitemid 44288070)
33. Karasek M et al. Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. Neuro Endocrinol Lett. 2002;1:55-60. (Pubitemid 34495383)
34. Oprea-Ilies G et al. 2013, Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. 137;677-687.
35. Qiagen. RNeasy ® Plus Mini Handbook. Limburg: Qiagen; 2010.
36. Mowla S et al. Evaluating expression and potential diagnostic and prognostic values of survivin in bladder tumors: a preliminary report. Urol J. 2005;2:141-7.
37. Mistry T. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl2 expression. BJU Int. 2008;101(10):1317-22. (Pubitemid 351549632)
38. Behjati F et al. Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women. Pathol Oncol Res. 2005;11(3):157-63. (Pubitemid 41564562)
39. Barni S, Lissoni P, Crispino S. Neouroimmunomodulation in cancer patients: correlation between melatonin and beta-endorphin blood levels and T-helper/suppressor ratio. J Biol Markers. 1988;3:82-6.
40. Cois S et al. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58:4383-90.
41. Radomir M et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351:152-66.
42. Lanoix D, Ouelette R, Vaillancourt C. Expression of melatoninergic receptors in human placental choriocarcinoma cell line.Hum Reprod. 2006;21:1981-89. (Pubitemid 44288070)
43. Pandi-perumal, S., s. V, and G. Maestroni, 2006. Melatonin: nature's most versatile biological signal? FEBS J. 273; 2813-2838.
44. González A et al. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep. 2007;17:947-53.
45. Yuan L et al. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002;192:147-56. (Pubitemid 34667233)
46. Collins A et al. Over-expression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibitsmammary tumor formation in nude mice. Cancer Lett. 2003;189:49-57. (Pubitemid 35351519)
47. Quastel MR, Rahamimoff R. Effect of melatonin on spontaneous contractions and response to 5-hydroxytryptamine of rat isolated duodenum. Br Pharmacol Chemother. 1995;24:455-61.
48. Rodriguez C et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1-9. (Pubitemid 38130283)